Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B

Circulation

Volumn 88, Issue 6, 1993, Pages 2744-2753

  Zhao, Xue Qiao ^a   Brown, B Greg ^a   Hillger, Lynn ^a   Sacco, Dianne ^a   Bisson, Brad ^a   Fisher, Lloyd ^a   Albers, John J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Cardiovascular diseases; Coronary disease; Lipids; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOPROTEIN; CHOLESTEROL; COLESTIPOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; HYPERLIPOPROTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; COLESTIPOL; CORONARY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; EXERCISE TEST; HUMAN; HYPERLIPOPROTEINEMIA; LOVASTATIN; MALE; MIDDLE AGE; NIACIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027495399     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.88.6.2744     Document Type: Article

References (46)

1. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
2. Canner PL, Berge KG, Wenger NK, Stamler J, Fnedman L, Prineas RJ, Friedewald W. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
3. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm ischemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
4. Buchwald HR, Varco L, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD, Sawin HS, Campos CT, Hansen BJ, Tuna N, Karnegis JN, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Bissett JK, Weber FJ, Stevenson JW, Leon AS, Chalmers TC, and the POSCH group. Effect of partial ileal bypass on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med. 1990;323:946-955.
5. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results, I: reduction in incidence of coronary heart disease. JAMA. 1984;251:351-364.
6. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Hultunen JK, Kaitaniemi P, Koskmen P, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260:641-651.
7. Brensike JF Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, Fisher MR, Friedman L, Friedewald W, Detre KM, Epstein SE. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
8. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of colestipol niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
9. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary heart disease? Lancet. 1990; 336:129-133.
10. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
11. Cashin-Hemphill L, Mack WJ, Pogoda MJ, Sanmarco ME, Azen SP, Blankenhorn DH. Beneficial effects of colestipol-niacin on coronary atherosclerosis. JAMA. 1990;264:3013-3017.
12. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264:3007-3012.
13. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339: 563-569.
14. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Pearce MB, Bissett JK, Edmiston WA, Sawin HS, Weber FJ, Varco RL, Campbell GS, Yellin AE, Smink RD, Long JM, Hansen BJ, Chalmers TC, Meier P, Stamler J. Change in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268: 1429-1433.
15. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87: 1067-1076.
16. American Heart Association Nutrition Committee and Council on Arteriosclerosis. Joint statement: recommendations for treatment of hyperlipidemia in adults. Circulation. 1984;69:1065A-1090A.
17. Dennis B, Ernst N, Hjortland M, Tillotson J, Gramlosch V. The NHLBI nutrition data system. J Am Diet Assoc. 1980;77:641-647.
18. Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. In: Albers JJ, Segrest JP, eds. Methods in Enzymology. Orlando, Fla: Academic Press, Inc; 1986:101-123.
19. Albers JJ, Cabana VG, Hazzard WR. Immunoassay of human plasma apolipoprotein B. Metabolism. 1975;24:1339-1351.
20. Cheung MC, Albers JJ. The measurement of apolipoprotein A1 and A2 levels in men and women by immunoassay. J Clin Invest. 1977;60:43-50.
21. Albers JJ, Dolphson JL, Hazzard WR. Radioimmunoassay of human plasma Lp(a) lipoprotein. J Lipid Res. 1977;18:331-338.
22. Bruce RA. Exercise testing of patients with coronary artery disease: principles and normal standard for evaluation. Ann Intern Med. 1971;3:323-332.
23. Brown BG, Bolson EL, Dodge HT. Quantitative computer techniques for analyzing coronary arteriograms. Prog Cardiovasc Dis. 1986;28:403-418.
24. Brown BG, Hillger LA, Zhao XQ, Sacco D, Bisson BD, Fisher LD. A maximum confidence strategy for measuring progression and regression of coronary artery disease in clinical trials. In: Reiber JHC, Serruys PQ, eds. Quantitative Coronary Arteriography. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1992.
25. SAS Institute, Inc. SAS User's Guide: Statistics, Version 5. Cary, NC: SAS Institute, Inc; 1985:607-614.
26. Rosner B. Fundamentals of Biostatistics. 2nd ed. Boston, Mass: Duxbury Press; 1969:326-332.
27. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without pre-existing cardiovascular disease. N Engl J Med. 1990;322:1707.
28. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen J. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med. 1989;320:904-910.
29. Dawber TR. The Framingham Study: The Epidemiology of Atherosclerotic Disease. Cambridge, Mass: Harvard University Press; 1980.
30. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med. 1990;323: 1112-1119.
31. Oliver MF. Might treatment of hypercholesterolaemia increase non-cardiac mortality? Lancet. 1991;337:1529-1531.
32. The National Heart, Lung, and Blood Institute: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
33. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res. 1966;61:1-17.
34. Tracey RE, Devaney K, Kissling G. Characteristics of the plaque under a coronary thrombus. Virchows Arch A Pathol Anat. 1985; 405:411-427.
35. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82(suppl II):II-38-II-46.
36. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;3:941-944.
37. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes: part 1. N Engl J Med. 1992;326:242-250.
38. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes: part 2. N Engl J Med. 1992;326:310-318.
39. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993; 87:1781-1791.
40. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
41. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol. 1990;16:349-356.
42. Manning WJ, Li W, Boyle NG, Edelman RR. Fat-suppressed breath-hold magnetic resonance coronary angiography. Circulation. 1993;87:94-104.
43. Tobis JM, Mallery J, Mahon D, Lehmann K, Zalesky P, Griffith J, Gessert J, Moriuchi M, McKal M, Dwyer ML, Greep N, Henry WL. Intravascular ultrasound imaging of human coronary arteries in vivo. Circulation. 1991;83:913-926.
44. Fitzgerald PJ, Goar FG, Connolly AJ, Pinto FJ, Billingham ME, Popp RL, Yock PG. Intravascular ultrasound imaging of coronary arteries. Circulation. 1992;86:154-158.
45. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusef S. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation. 1992;86:1046-1060.
46. Hulley SB, Walsh JMB, Newman TB. Health policy on blood cholesterol. Circulation. 1992;86:1026-1029.